Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPTION: Consolidation Chemotherapy Before Local Excision in Stage I Rectal Cancer
NCT07563907Not yet recruiting
- Sponsor
- Seoul National University Hospital
- Start
- Jun 2026
- Primary completion
- Dec 2030
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Randomised trial of capecitabine in rectal cancer (2 arms), sponsored by Seoul National University Hospital. Primary endpoint: Pathologic complete response rate at 10 weeks. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
capecitabine
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT07563907.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07563907.